Researchers see promise in transplanted fetal stem cells for Parkinson's

June 5, 2014, McLean Hospital

Researchers at Harvard-affiliated McLean Hospital have found that fetal dopamine cells transplanted into the brains of patients with Parkinson's disease were able to remain healthy and functional for up to 14 years, a finding that could lead to new and better therapies for the illness.

The discovery, reported in the June 5, 2014 issue of the journal Cell Reports, could pave the way for researchers to begin transplanting neurons taken from grown in laboratories, a way to get treatments to many more in an easier fashion.

"We have shown in this paper that the transplanted cells connect and live well and do all the required functions of nerve cells for a very long time," said Ole Isacson, MD (DR MED SCI), director of the Neuroregeneration Research Institute at McLean and a professor of neurology and neuroscience at Harvard Medical School.

The researchers looked at the brains of five patients who got fetal over a period of 14 years and found that their dopamine transporters (DAT), proteins that pump the neurotransmitter dopamine, and mitochondria, the power plants of cells, were still healthy at the time the patients died, in each case of causes other than Parkinson's.

The fact that these cells had remained healthy indicated that the transplants had been successful and that the transplanted cells had not been corrupted as some researchers had suggested they likely had been in other studies, said Dr. Isacson, lead author of the paper.

"These findings are critically important for the rational development of stem cell-based dopamine neuronal replacement therapies for Parkinson's," the paper concluded.

So far, about 25 patients worldwide have been treated with this particular method of transplanting fetal dopamine cells over a period of two decades and most saw their symptoms improve markedly, he said.

Fetal cell transplants can reduce both Parkinson's symptoms for many years and can reduce the need for dopamine replacement drugs, even though they can take months or years to start working, the paper said.

However, Dr. Isacson said proof had been lacking that the transplanted cells were able to remain healthy—until this study. This is important for research in the transplant field to move ahead, he said.

All of the patients were in the late stages of Parkinson's disease at the time of their transplants. Parkinson's is a disease characterized by tremors, rigidity, slowness of movement and poor balance. It is a chronic, progressive disease that results when dopamine-producing nerve cells in a part of the brain die or are impaired.

Dr. Isacson said there was a need to understand how transplanted neurons could survive despite ongoing disease process in the patients' brains. He said there has been controversy among scientists, some of whom believe that the transplanted cells could be corrupted by toxic proteins associated with the disease process, even at the same time patients seemed to be doing better.

"Everything we saw looked very healthy," he said, referring to the dopamine transporters and mitochondria cells.

He said the method used to transplant the cells into these patients' brains was different than another method used on about 60 other patients worldwide. In some of those other trials, scientists said the cells might have been damaged as a result of the disease process.

It may have been that the method used on the patients in this study, which injected tiny bits of liquefied dopamine nerve cells into the brain via a thin needle, was superior to the method used in other studies, which transplanted larger chunks of nerve cells using a larger needle, he said. The transplants on the patients in this study were done in Canada.

In this study, the researchers led by Dr. Isacson compared the patients' own dopamine producing cells with the transplanted ones. "We found very different patterns," he said.

The difference was seen in the DAT and mitochondria, which were unhealthy around the patients' own and healthy around the transplanted ones. "The transplanted cells don't have the disease," he said.

"This is very important in the quest for new therapies," he added.

It is very difficult to obtain dopamine from fetal tissue, he said. It would be far easier to grow the cells in a laboratory from stem , he noted. There have been no stem cell transplants as of yet for Parkinson's patients.

Explore further: Dopamine-producing neurons derived from bone marrow stem cells yield improvements in monkeys with Parkinson's disease

More information: Cell Reports, Hallett et al.: "Long-term dopamine transporter expression and normal cellular distribution of mitochondria in dopaminergic neuron transplants in Parkinson's disease patients.", www.cell.com/cell-reports/abst … 2211-1247(14)00419-7

Related Stories

Dopamine-producing neurons derived from bone marrow stem cells yield improvements in monkeys with Parkinson's disease

April 22, 2013
Parkinson's disease is a neurodegenerative disorder characterized by the death of dopamine-producing neurons in the midbrain, resulting in motor symptoms such as tremors and stiffness. The cause of cell death remains unknown ...

Identification of dopamine 'mother cells' could lead to future Parkinson's treatments

April 7, 2008
‘Mother cells’ which produce the neurons affected by Parkinson’s disease have been identified by scientists, according to new research published in the journal Glia.

Stimulating brain cells with light

October 26, 2012
For the time being, this is basic research but the long term objective is to find new ways of treating Parkinson's disease. This increasingly common disease is caused by degeneration of the brain cells producing signal substance ...

Serotonin solves decades-old mystery in Parkinson's disease

June 30, 2010
Sudden, uncontrolled movements called dyskinesias—a common side effect of treatment for Parkinson’s disease— are a result of excess serotonin cells in transplanted tissue that trick the brain into releasing dopamine, ...

Grant for research that could lead to new therapies for Parkinson's Disease

April 22, 2014
A team of scientists led by researchers at Plymouth University Peninsula Schools of Medicine and Dentistry, has received a grant from the Medical Research Council (MRC) for work which could lead to new and effective therapies ...

New treatment targeting versatile protein may protect brain cells in Parkinson's disease

May 16, 2014
In Parkinson's disease (PD), dopamine-producing nerve cells that control our movements waste away. Current treatments for PD therefore aim at restoring dopamine contents in the brain. In a new study from Lund University, ...

Recommended for you

New transgenic model of Parkinson's illuminates disease biology

October 11, 2018
Parkinson's disease (PD) is a neurodegenerative disorder that presents clinically with abnormal movement and tremors at rest. In the brain, PD is marked by the accumulation of the protein, α-synuclein (αS), into clumps ...

Early Parkinson's patients waiting too long to seek medical evaluation

September 27, 2018
The time between diagnosis and the institution of symptomatic treatment is critical in the effort to find a cure for Parkinson's Disease (PD). A paper published in Nature Partner Journal: Parkinson's Disease notes too many ...

Molecule capable of halting and reverting neurodegeneration caused by Parkinson's disease identified

September 25, 2018
The small SynuClean-D molecule interrupts the formation of the alpha-synuclein amyloid fibres responsible for the onset of Parkinson's disease, and reverts the neurodegeneration caused by the disease. The study, headed by ...

Genomic dark matter activity connects Parkinson's and psychiatric diseases

September 20, 2018
Dopamine neurons are located in the midbrain, but their tendril-like axons can branch far into the higher cortical areas, influencing how we move and how we feel. New genetic evidence has revealed that these specialized cells ...

Gene therapy shown to remove core component of Parkinson's disease

September 14, 2018
An international team led by Rush researcher Jeffrey Kordower, Ph.D., has moved a step closer to developing a treatment to clear brain cells of a protein that is an integral cause of Parkinson's disease. The team published ...

ADHD may increase risk of Parkinson's disease and similar disorders

September 12, 2018
While about 11 percent of children (4-17 years old) nationwide have been diagnosed with attention-deficit hyperactivity disorder (ADHD), the long-term health effects of having ADHD and of common ADHD medications remains understudied. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.